TOP TEN perturbations for 39216_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39216_at
Selected probe(set): 214640_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39216_at (214640_at) across 6674 perturbations tested by GENEVESTIGATOR:

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-3.4519548
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-2.9160848
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):2.8031087
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

cutaneous T-cell lymphoma study 1 (tumor phase) / cutaneous T-cell lymphoma study 1 (patch phase)

Relative Expression (log2-ratio):-2.7128744
Number of Samples:4 / 2
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control cutaneous T-cell lymphoma study 1 (patch phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the patch phase.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; placebo; 15d)

Relative Expression (log2-ratio):-2.677309
Number of Samples:8 / 5
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 15d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with placebo.

psoriasis study 5 (NCT00867100; lesional; baseline) / psoriasis study 5 (NCT00867100; non-lesional; baseline)

Relative Expression (log2-ratio):2.4141903
Number of Samples:24 / 24
Experimental psoriasis study 5 (NCT00867100; lesional; baseline)
Lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from lesional skin at baseline.
Control psoriasis study 5 (NCT00867100; non-lesional; baseline)
Non-lesional skin punch biopsies derived from patients (Set 2 of clinical trial NCT00867100; aged 19-55) with moderate to severe plaque psoriasis (over more than 10% of body surface area and a PASI score greater 10). A 6mm punch biopsy was obtained from uninvolved, non-lesional skin at baseline.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; placebo; 43d)

Relative Expression (log2-ratio):-2.353788
Number of Samples:8 / 4
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 43d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with placebo.

psoriasis study 11 (lesional; baseline) / psoriasis study 11 (non-lesional; baseline)

Relative Expression (log2-ratio):2.3052855
Number of Samples:25 / 24
Experimental psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.
Control psoriasis study 11 (non-lesional; baseline)
Non-lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

hepatocyte (ESC) / Hep-G2

Relative Expression (log2-ratio):2.2287626
Number of Samples:8 / 9
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):2.2039642
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

Organism: Homo sapiens
Gene: 39216_at
Selected probe(set): 214382_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39216_at (214382_at) across 6674 perturbations tested by GENEVESTIGATOR:

hepatocyte (ESC) / HepaRG

Relative Expression (log2-ratio):5.2463713
Number of Samples:8 / 12
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-3.8129559
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

colorectal cancer study 33 (carcinoma; colonic mucosa) / normal colon mucosa sample

Relative Expression (log2-ratio):3.775712
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colon mucosa sample
Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

colorectal cancer study 33 (carcinoma; colonic mucosa) / adjacent colon mucosa sample

Relative Expression (log2-ratio):3.626917
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colon mucosa sample
Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic) / endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic)

Relative Expression (log2-ratio):-3.4676418
Number of Samples:3 / 2
Experimental endometrial cancer study 1 (PDX; carcinosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinosarcoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control endometrial cancer study 1 (PDX; adenocarcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary adenocarcinoma, NOS of the endometrium (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-3.421999
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; AG1478)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:---
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

skin transplantation study 1 (3d) / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-3.2816172
Number of Samples:6 / 8
Experimental skin transplantation study 1 (3d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 3 days after surgery.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (15d)

Relative Expression (log2-ratio):-3.2175512
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.

hepatocyte-like cell differentiation study 1 (15d) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):3.2149467
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

colorectal cancer study 33 (carcinoma; colonic crypt) / adjacent colonic crypt epithelial cell sample

Relative Expression (log2-ratio):3.1106577
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colonic crypt epithelial cell sample
Adjacent colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from patients with colorectal cancer.